by The global Infectious Disease Therapeutics Market is estimated to be valued at US$ 170.67 Bn or Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Infectious disease therapeutics are drugs used for the treatment of various infectious diseases caused by pathogens like bacteria, viruses, fungi or parasites. These therapeutics aid in eliminating or weakening the causative pathogens and help patients recover faster. The need for effective infectious disease therapeutics have increased globally due to rising prevalence of infectious diseases.
Market key trends:
One of the key trends in the infectious disease therapeutics market is the rising focus on developing novel drug candidates for antimicrobial resistance treatment. Drug resistance has emerged as a major challenge in the treatment of infectious diseases. According to the World Health Organization, antimicrobial resistance jeopardizes decades of progress in medicine and may lead to a post-antibiotic era. To address this, leading market players are focusing on developing newer treatment options for drug-resistant microbial infections through partnerships and collaborations. For instance, in 2022 Pfizer started three collaborations with Entasis Therapeutics, Paratek Pharmaceuticals and Evotec to develop new antibiotics targeting priority pathogen species listed by the WHO.
key trends:
One of the key trends in the infectious disease therapeutics market is the rising development of advanced therapies such as small molecule drugs, monoclonal antibodies, and gene therapies. These advanced therapies have shown potential to effectively treat chronic infectious diseases such as HIV/AIDS, hepatitis, tuberculosis, etc. For example, monoclonal antibodies targeting specific viruses have demonstrated high success rates in clinical trials. In addition, gene therapies aimed at fixing genetic defects have emerged as promising treatments for diseases like SCID (severe combined immunodeficiency).
SWOT Analysis
Strengths: Large patient pool suffering from infectious diseases globally. Significant R&D investments by leading players for drug development.
Weaknesses: High costs associated with developing and manufacturing advanced therapies. Stringent regulatory processes can delay drug approvals.
Opportunities: Emergence of novel drug targets and diagnostic techniques. Growing healthcare expenditures in developing countries.
Threats: Patent expiries of blockbuster drugs. Risk of pandemics and outbreaks of new infectious diseases.
Key Takeaways
The Global Infectious Disease Therapeutics Market Size is expected to witness high growth, exhibiting CAGR Of 3.7% over the forecast period, due to increasing investment in R&D of new drug classes.
The North American region currently dominates the infectious disease therapeutics market owing to rising prevalence of lifestyle diseases and favorable reimbursement policies. Going forward, Asia Pacific region is likely to be the fastest growing market due to improving access to healthcare facilities along with increasing disposable incomes.
Key players operating in the infectious disease therapeutics market are Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland), Sanofi (France). These players are focusing on developing novel drug variants through heavy investments in R&D activities.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
